Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.
about
Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherenceFrom Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.A fungicidal monoclonal antibody protects against murine invasive candidiasis.Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasisEnhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragmentAntibody Peptide based antifungal immunotherapyAnticandidal immunity and vaginitis: novel opportunities for immune intervention.Synthesis and immunological studies of linear oligosaccharides of β-glucan as antigens for antifungal vaccine developmentA novel glyco-conjugate vaccine against fungal pathogens.Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy.Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine.Adjuvanticity of a recombinant calreticulin fragment in assisting anti-β-glucan IgG responses in T cell-deficient mice.Interactions of the fungal pathogen Candida albicans with the host.Saccharomyces cerevisiae: a versatile eukaryotic system in virology.Controlling pathogenic inflammation to fungi.Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis.Potential of anti-Candida antibodies in immunoprophylaxis.Antibody-Fc receptor interactions in protection against intracellular pathogens.The protective role of immunoglobulins in fungal infections and inflammation.Antibodies as a source of anti-infective peptides: an update.Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infectionPlant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans.Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.The importance of the phagocytes' innate response in resolution of the infection induced by a low virulent Candida albicans mutant.The 65 kDa mannoprotein gene of Candida albicans encodes a putative beta-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity.
P2860
Q24625384-C68348FE-271B-4B65-8485-B1F6419FC878Q30862390-BF245950-6F86-4AB2-8BC7-82A93F222BFDQ33660397-B31217B5-1DBE-4320-8E0E-C5535D4F5996Q33675896-B19C9273-E938-4FFA-94AC-DB8A681A5979Q33798458-DE293FAF-49EA-487C-B830-8F136BB32CBCQ34601994-888CF5EF-750D-44A7-9D00-063C234A3F57Q34721320-7090ACB0-6856-49DE-A343-3EC1E094419CQ34946997-62AC248B-75D5-4E80-B0AE-C2198C4FF19DQ36003400-E825EB4F-C4D2-4FF2-81A5-56884DD3B9ECQ36097307-B20CE7F0-52C9-4B7B-BB42-DBFE7490D7CBQ36331649-8B6C46AC-8EAA-4F48-A04F-50447DBBAEBDQ36402820-DF5FDCB3-C1E7-4A2E-A8C3-9875576BB91FQ36569737-25559932-44EC-4E16-87BE-37A55343350EQ36690302-302AC2A1-7C96-4DA5-9827-E1E1255EF42AQ36757877-9E1D1497-36BB-49C7-9944-A294F1AF2846Q36895656-B1E676AE-62A9-48D5-A513-E7E8B505A6B5Q36967384-DF2D49FA-9CA6-4F75-91FD-C84255B69301Q37014666-FE5F531F-131D-42C5-B1DA-93D7867CD922Q37014861-D855142A-1327-4629-B3F9-F9F08BDC2F61Q37773252-B8FF36A9-FDD4-4175-8D16-6ACDDD72F3A0Q37853942-5F9B54B6-C771-4242-B023-D6465E33D2BFQ38268922-32D27125-7FD3-4514-B086-A28E68DE64D6Q38539513-F4A97E36-A8E0-4BD9-AC13-2AB4F097FC6EQ38603068-A01E19A7-FF39-4021-9CD2-2B523CFCB5E0Q39603076-82FB3B22-C7F8-4616-AE67-532ADEEC01ECQ44792128-633EBA59-097C-414F-B90C-5CE7D9826734Q46716413-86499236-D8C2-44CE-9533-4F921CAA9543Q54562824-07BA0F5B-7D2F-4F1B-9C85-C86589842FD5
P2860
Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interplay between protective a ...... of a Candida albicans vaccine.
@ast
Interplay between protective a ...... of a Candida albicans vaccine.
@en
Interplay between protective a ...... of a Candida albicans vaccine.
@nl
type
label
Interplay between protective a ...... of a Candida albicans vaccine.
@ast
Interplay between protective a ...... of a Candida albicans vaccine.
@en
Interplay between protective a ...... of a Candida albicans vaccine.
@nl
prefLabel
Interplay between protective a ...... of a Candida albicans vaccine.
@ast
Interplay between protective a ...... of a Candida albicans vaccine.
@en
Interplay between protective a ...... of a Candida albicans vaccine.
@nl
P2093
P2860
P1476
Interplay between protective a ...... of a Candida albicans vaccine.
@en
P2093
Antonella Torosantucci
Antonio Cassone
Carla Bromuro
Luciano Polonelli
Paola Chiani
Stefania Conti
P2860
P304
P356
10.1128/IAI.70.10.5462-5470.2002
P407
P577
2002-10-01T00:00:00Z